<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849132</url>
  </required_header>
  <id_info>
    <org_study_id>2016ZX10002011</org_study_id>
    <nct_id>NCT02849132</nct_id>
  </id_info>
  <brief_title>Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients</brief_title>
  <official_title>Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Yanbian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <brief_summary>
    <textblock>
      Patients who have completed 2 years follow-up of the past National 12th Five-Year Major&#xD;
      Project on Infectious Diseases will receive another 8 years treatment with entecavir (10&#xD;
      years in total). Collect serology, imaging, and other clinical data to evaluate the incidence&#xD;
      and mortality of decompensated cirrhosis and hepatocellular carcinoma. Understand the effects&#xD;
      of long-term antiviral therapy on HBV-induced liver fibrosis/cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have completed 2-years entecavir-based treatment in Regress Study will receive&#xD;
      another 8 years of entecavir extension therapy. Patients will be assessed at baseline and&#xD;
      every six months for blood cell count, liver function test, HBV-DNA, AFP, prothrombin time,&#xD;
      liver ultrasonography, and Fibroscan; A third liver biopsy will be performed at the 5th year&#xD;
      of treatment in patients who have significant fibrosis at second biopsy. CT /MRI and&#xD;
      endoscopy will be performed at baseline and the 5th and 10th year of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis regression rate</measure>
    <time_frame>year 3</time_frame>
    <description>Ishak fibrosis score decrease after long-term treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of liver decompensation</measure>
    <time_frame>year 8</time_frame>
    <description>Cumulative incidence of liver decompensation (including ascites, hepatic encephalopathy, esophageal varices bleeding and Hepatocellular Carcinoma) and death after long-term treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>Percentage of patients achieving hepatitis B virus (HBV) DNA &lt; 20IU/mL at year 3, 5, 7 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aminotransferase response</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>The percentage of patients with alanine aminotransferase (ALT) normalization at year 3, 5, 7 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss or HBeAg seroconversion</measure>
    <time_frame>year 2, 5, 7 and 10</time_frame>
    <description>Percentage of patients with HBeAg loss or HBeAg seroconversion at year 2, 5, 7 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss or HBsAg seroconversion rate</measure>
    <time_frame>year 2, 5, 7 and 10</time_frame>
    <description>Percentage of patients with HBsAg loss or HBsAg seroconversion at year 2, 5, 7 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of Child-Pugh score</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>Dynamic changes of Child-Pugh score after 3, 5, 7 and 10 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of MELD score</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>Dynamic changes of MELD score after 3, 5, 7 and 10 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of liver stiffness values measured by Transient Elastography</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>Dynamic changes of liver stiffness values after 3, 5, 7 and 10 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life quality (SF36 and EQ-5D)</measure>
    <time_frame>year 3, 5, 7 and 10</time_frame>
    <description>Improvement of life quality after 3, 5, 7 and 10 years of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir oralï¼Œ0.5mg daily for 8 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>oral entecavir 0.5mg daily for 8 years</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects who completed the 2 years of entecavir-based therapy in Regress study; Subjects&#xD;
        who are willing to participate the extension study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any complication of severe heart, lung, kidney, brain, blood diseases or other important&#xD;
        systematic diseases; Pregnant women; Subjects who could not compliance with the protocol&#xD;
        judged by investigators; Subjects who are not suitable for the study judged by&#xD;
        investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojuan Ou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NanfangHospital,Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Fifth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>50021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College , Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>30001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Xiqing Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300380</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5. doi: 10.1053/j.gastro.2010.06.019. Epub 2010 Jun 14.</citation>
    <PMID>20558165</PMID>
  </reference>
  <reference>
    <citation>Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.</citation>
    <PMID>15470215</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojuan Ou</investigator_full_name>
    <investigator_title>Vice-Director of Liver Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

